GlassScriptPhysician profile
Lisa Richardson
NPI 1992918726
$8,691.92
in general payments reported to CMS, 2019-2025
32 companies · $1,930 in 2025
The $1,930 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $1,117 · 2021: $978 · 2022: $959 · 2023: $1,515 · 2024: $1,458 · 2025: $1,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,902.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $902.51 | 2020-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $857.35 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $692.41 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $598.48 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $588.22 | 2020-2023 | Belsomra, Verquvo, Steglatro |
| Lundbeck LLC | $462.56 | 2021-2025 | Rexulti |
| Novo Nordisk INC | $453.57 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $409.86 | 2021-2025 | |
| Dexcom, INC. | $387.31 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $382.97 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbott Laboratories | $379.39 | 2024-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $323.82 | 2022-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $292.58 | 2021-2024 | |
| Glaxosmithkline, LLC. | $266.18 | 2020-2023 | Bexsero, Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $240.16 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.25 | 2019-2025 | Xifaxan, Relistor |
| Exact Sciences Corporation | $186.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $183.21 | 2022-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $177.59 | 2019-2022 | |
| Intuitive Surgical, INC. | $127.28 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $99.91 | 2025 | Austedo Xr |
| Pfizer INC. | $89.62 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.18 | 2021-2024 | |
| Allergan, INC. | $48.75 | 2019-2020 | |
| Sanofi Pasteur INC. | $48.01 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $45.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.04 | 2025 | Trintellix |
| Ardelyx, INC. | $34.72 | 2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $29.13 | 2019-2025 | Spravato |
| Nabriva Therapeutics, Plc | $22.25 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.59 | 2019 | |
| Daiichi Sankyo INC. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.